The Marcus (MCS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
The annual meeting will be held virtually on May 21, 2026, with shareholders voting on director elections, executive compensation, and auditor ratification.
Shareholders of record as of March 24, 2026, are entitled to vote, with Class B shares carrying ten votes per share and Common shares one vote per share.
Proxy materials are available online, and shareholders are encouraged to review all information before voting.
Voting matters and shareholder proposals
Shareholders will vote to elect twelve directors, approve executive compensation by advisory vote, and ratify Deloitte & Touche LLP as independent auditor for fiscal 2026.
No shareholder proposals or nominations were received for this meeting.
The board recommends voting in favor of all proposals.
Board of directors and corporate governance
The board consists of twelve members, with a mix of management and independent directors; Philip L. Milstein serves as Lead Independent Director.
Board committees include Audit, Compensation, Corporate Governance and Nominating, and Finance, each with defined charters and independent membership.
Directors are expected to attend meetings and the annual meeting; most attended at least 75% of meetings in 2025.
The company maintains a Code of Conduct and insider trading policy applicable to all directors and employees.
Latest events from The Marcus
- Strong 2026 results, asset reinvestment, and growth strategies drive shareholder value.MCS
Investor presentation - Q2 2026 set post-pandemic records for revenue and profit, with both divisions outpacing industry growth.MCS
Q2 2026 - Board, compensation, and auditor votes passed overwhelmingly; no Q&A from shareholders.MCS
AGM 2026 - Revenue grew 3.8% as both divisions outperformed, with improved losses and strong cash flow.MCS
Q1 2026 - Virtual annual meeting to vote on directors, pay, and auditor ratification, all board-backed.MCS
Proxy filing - 2025 revenue reached $758.5M with strong theatre and hotel performance and robust growth outlook.MCS
Investor presentation - Both divisions outperformed peers in 2025, with strong revenue growth and a robust 2026 outlook.MCS
Q4 2025 - Q2 revenue fell 15% as hotels outperformed and theaters rebounded with improved film supply.MCS
Q2 2024 - Q1 revenue up 7.4% to $148.8M, but net loss widened to $16.8M on higher costs.MCS
Q1 2025